Author

V. Doma

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Assay:proteomics· 4 Research Focus:drug response / drug discovery· 3 Approach:statistical model· 3 Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

A. Sanchez· 4 shared E. Wieslander· 4 shared J. Gil· 4 shared J. Malm· 4 shared R. Appelqvist· 4 shared S. Karpati· 4 shared Y. Kim· 4 shared A. M. Szasz· 3 shared

Activity by Year

2021-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

A. Sanchez

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Predicting immune checkpoint therapy response in three independent metastatic melanoma cohorts

L. Szadai, A. Bartha, I. P. Parada, A. Lakatos, D. Pal, A. S. Lengyel, N. P. d. Almeida, A. J. Janosi, F. Nogueira, B. Szeitz, V. Doma, N. Woldmar, J. Guedes, Z. Ujfaludi, Z. G. Pahi, , A. Sanchez

The paper identifies six proteins that predict response to immune checkpoint therapy across three melanoma cohorts and correlate with patient survival.

bioRxiv · May 1, 2024Cancer Biology

Identifying Ferroptosis Inducers, HDAC, and RTK Inhibitor Sensitivity in Melanoma Subtypes through Unbiased Drug Target Prediction

I. Pla, B. L. Szabolcs, P. N. Peter, Z. Ujfaludi, Y. Kim, P. Horvatovich, A. Sanchez, K. Pawlowski, E. Wieslander, J. Guedes, D. M. Pal, A. A. Ascsillan, L. H. Betancourt, I. B. Nemeth, J. Gil, , L. V. Kemeny

This paper identifies potential drug targets and predicts treatment efficacy and resistance in melanoma subtypes using proteogenomic data and drug sensitivity analysis.

bioRxiv · Feb 8, 2024 · PreprintCancer Biology

Proteogenomic Characterization Reveals Therapeutic Opportunities Related to Mitochondrial Function in Melanoma

J. Gil, Y. Kim, V. Doma, U. Cakır, M. Kuras, L. Betancourt, I. Pla Parada, A. Sanchez, Y. Sugihara, R. Appelqvist, H. Oskolas, B. Lee, J. de Siqueira Guedes, G. Monnerat, G. Reis Alves Carneiro, , G. Marko-Varga

This study uses proteomics to analyze mitochondrial function in melanoma samples, finding dysregulation linked to patient survival and treatment responses, and proposes therapeutic strategies targeting mitochondrial pathways.

bioRxiv · Oct 24, 2022 · PreprintCancer Biology

Proteogenomics Reveals how Metastatic Melanoma Modulates the Immune System to Allow Immune Evasion

J. Gil, Y. Kim, B. Szeitz, V. Doma, U. Cakır, N. Pinto de Almeida, Y. Paco Hagemeijer, V. Guryev, J. G. Johansson, Y. Sharma, I. Pla Parada, Z. Horvath, J. de Siqueira Guedes, G. Monnerat, F. C. Nogueira, , G. Marko-Varga

This paper analyzes proteogenomic data from melanoma patients to show how metastatic melanoma alters metabolism and immune responses to evade immune detection.

bioRxiv · Apr 10, 2021 · PreprintCancer Biology